

May 31, 2022

Guangzhou Easycess Medical Co., Ltd Xingcheng Liu Manager of Registration Affairs Department Room 701, Building B4, 11 Kaiyuan Avenue, Huangpu District, Guangzhou, 510530 China

Re: K213065

Trade/Device Name: Distal Access Catheter Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous Catheter

Regulatory Class: Class II Product Code: QJP, DQY Dated: April 28, 2022 Received: May 5, 2022

## Dear Xingcheng Liu:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <a href="https://www.accessdata.fda.gov/scripts/cdrh/efdocs/efpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/efdocs/efpmn/pmn.cfm</a> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <a href="https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products">https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products</a>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems">https://www.fda.gov/medical-device-problems</a>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</a>) and CDRH Learn (<a href="https://www.fda.gov/training-and-continuing-education/cdrh-learn">https://www.fda.gov/training-and-continuing-education/cdrh-learn</a>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</a>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Naira Muradyan, Ph.D.
Assistant Director
DHT5A: Division of Neurosurgical,
Neurointerventional
and Neurodiagnostic Devices
OHT5: Office of Neurological
and Physical Medicine Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

# DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

# Indications for Use

510(k) Number (if known)

Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023

Expiration Date: 06/30/2023 See PRA Statement below.

K213065		
Device Name Distal Access Catheter		
idications for Use (Describe) The Distal Access Catheter is indicated for general intravascular use, including the neuro and peripheral vasculature. It an be used to facilitate introduction of diagnostic agents or therapeutic devices. It is not intended for use in coronary reteries.		
Type of Use (Select one or both, as applicable)		
Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)  CONTINUE ON A SEPARATE PAGE IF NEEDED.		

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

# 510(k) Summary K213065

#### I. SUBMITTER

Guangzhou Easycess Medical Co., Ltd

Room 701, Building B4, 11 Kaiyuan Avenue, Huangpu District,

Guangzhou, China, 510530

Phone: 020-31603990 Fax: 020-31603675

Contact Person: Xingcheng Liu Date of Preparation: May 30th, 2022

#### II. DEVICE

Name of Device: Distal Access Catheter

Common or Usual Name: Distal Access Catheter

Classification Name: Percutaneous catheter (21 CFR 870.1250)

Regulatory Class: II Product Code: QJP, DQY

#### III. PREDICATE DEVICE

Primary predicate device: SOFIA PLUS/Distal Access Catheter (K150366) Secondary predicate device: SOFIA Distal Access Catheter (K131482, K142014)

These predicate devices have not been subject to a design-related recall.

No reference devices were used in this submission.

#### IV. DEVICE DESCRIPTION

The Distal Access Catheter consists of a catheter and accessories (hemostatic valve, introducer sheath, and a shaping mandrel). The catheter is a single-lumen, flexible catheter designed with coil and braid reinforcement. The distal segment is steam-shapeable, and a hydrophilic coating is applied for navigation of the catheter through the vasculature. The radiopaque marker is located at the distal end of the catheter for visualization under fluoroscopy.

The catheter body is constructed with a stainless-steel coil (less 2 cm of the catheter length) over the inner lumen liner comprised of polytetrafluoroethylene (PTFE). To provide additional shaft support, a stainless-steel wire braiding has been added over the stainless-steel coil from the proximal end to distal end. A platinum/iridium alloy radiopaque marker band is located at the distal tip of the catheter. An outer layer of varying durometers and lengths of polyamide (PA), polyether block amide (Pebax) and polyurethane (PU) covers the entire catheter body from proximal to distal end, respectively.

A hub (PC) is attached to the proximal end of the catheter. A strain relief made from polyether block amide (Pebax) is placed at the proximal end of the catheter and distal

end of the hub. The hub-strain relief provides for the kink resistance for the proximal end. A luer fitting on the catheter hub is used for the attachment of accessories.

The outer surface of the catheter (distal 60 cm) is coated with a hydrophilic coating to reduce friction during navigation in the vasculature.

A shaping mandrel (stainless steel, 80 mm in length) is provided with the catheter to be used by the physician for tip shaping. An introducer sheath (PTFE) is included to facilitate the introduction of the catheter into guide catheters during clinical use. A hemostatic valve is used to connect to the proximal section of the catheter.

The Distal Access Catheter is provided sterile and for single use only. The catheter is placed in a dispenser tube (HDPE) and is placed on a packaging card (HDPE) that is provided in a sterile barrier PET/PE film and Tyvek pouch and placed in a carton box.

#### V. INDICATIONS FOR USE

The Distal Access Catheter is indicated for general intravascular use, including the neuro and peripheral vasculature. It can be used to facilitate introduction of diagnostic agents or therapeutic devices. It is not intended for use in coronary arteries.

# VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE

Technological Comparison:

Device name		SOFIA PLUS/Distal Access Catheter (K150366, Primary predicate device)	SOFIA Distal Access Catheter (K131482, K142014, Secondary predicate device)	Distal Access Catheter (K213065, Subject device)	
Intended	Use	The SOFIA PLUS /Distal Access Catheters are indicated for general intravascular use, including the neuro and peripheral vasculature. It can be used to facilitate introduction of diagnostic and therapeutic agents. It is not intended for use in coronary arteries.	The SOFIA Distal Access Catheter is intended for general intravascular use, including the neuro and peripheral vasculature. It can be used to facilitate the introduction of diagnostic and therapeutic agents. It is not intended for use in coronary arteries.	The Distal Access Catheter is indicated for general intravascular use, including the neuro and peripheral vasculature. It can be used to facilitate introduction of diagnostic agents or therapeutic devices. It is not intended for use in coronary arteries.	
	Catheter inner layer	PTFE, polyolefin elastomer	PTFE, polyolefin elastomer	PTFE	
Material	Catheter middle layer	Stainless steel braid/coil	Stainless steel braid/coil	Same	
	Catheter outer layer	Polyurethane elastomer, polyether block amide (Pebax) and polyamide	Polyurethane elastomer, polyether block amide (Pebax) and polyamide	Same	
	Marker	Platinum/Iridium	Platinum/Iridium	Same	
	Hub	Nylon	Nylon	PC	

Device name		SOFIA PLUS/Distal Access Catheter (K150366, Primary predicate device)	SOFIA Distal Access Catheter (K131482, K142014, Secondary predicate device)	Distal Access Catheter (K213065, Subject device)
	Strain Relief	Polyurethane	Polyurethane	Pebax
	Introducer	Pebax	Pebax	PTFE
	Shaping Mandrel	Stainless steel	Stainless steel	Same
	Hemostati c Valve	Not applicable	Not applicable	PC
Catheter	Size	6F	5F	5F 6F
Inner Dia	meter (ID)	0.070 inch (1.78 mm)	0.055 inch (1.4 mm)	5F: 0.056" (1.42mm) 6F: 0.071" (1.80mm)
Outer Diameter (OD)		0.0825 inch (2.1 mm)	0.068 inch (1.7 mm)	5F: 0.068" (1.73mm) 6F: 0.083" (2.11mm)
Effective	Length	115-135 cm	115-125 cm	115-135cm
Coating		Hydrophilic coating (Hydak®)	Hydrophilic coating (Hydak®)	Hydrophilic coating (Polyamide)
Tip Confi	guration	Steam shapeable by user	Steam shapeable by user	Same
Guidewire Compatibility		0.035 inch	0.035 inch or 0.038 inch	0.035 inch
Accessor	ies	Introducer sheath and shaping mandrel	Introducer sheath and shaping mandrel	Introducer sheath, shaping mandrel and hemostatic valve
Method o	f Supply	Sterile and single use	Sterile and single use	Same
Sterilizati	on Method	Ethylene Oxide	Ethylene Oxide	Same
Packaging Configuration		Catheter placed into a HDPE dispenser tube. Dispenser tube, introducer and shaping mandrel placed on a polyethylene packaging card that is inserted into a Tyvek® pouch. Pouch and IFU placed in bleached sulfate carton box.	Catheter placed into a HDPE dispenser tube. Dispenser tube, introducer and shaping mandrel placed on a polyethylene packaging card that is inserted into a Tyvek® pouch. Pouch and IFU placed in bleached sulfate carton box.	Catheter placed into a HDPE dispenser tube. Dispenser tube, introducer, shaping mandrel and hemostatic valve placed on a polyethylene packaging card that is inserted into a Tyvek/PE/PET pouch. Pouch and IFU placed in bleached sulfate carton box.

# VII. PERFORMANCE DATA

The following performance data were provided in support of the substantial equivalence determination.

# • Bench Testing and Sterility

The bench testing of the Distal Access Catheter was performed using the applicable sections of the ISO 10555-1 international standard for sterile, single-use intravascular catheters. The testing demonstrates that the in vitro behavior of the device is well characterized within design specifications. The results of bench testing and sterility

# evaluation are listed in the table below:

Test	Specification	Conclusion
Surface	The external surface of the catheter shall be free	The surface integrity is
Inspection	from extraneous matter. The external surface of	suitable for intended clinical
	the catheter, including the distal end, shall be	use.
	free from process and surface defects which	
	could cause trauma to vessels during use.	
Surface	The test article shall be free from surface	The surface integrity is
Contamination	contaminants from uncured coating surface	suitable for intended clinical
	particulates > 0.02 mm <sup>2</sup> , embedded particulates.	use.
	The distal tip shall be smooth and tapered. PTFE	
Dimensional	inner layer not delaminated.	The device met the
Verification	The device shall meet the specified dimensional	
verification	requirements, including catheter OD, catheter	dimensional and physical specifications.
	ID, effective length, length of distal tip and total length of accessories.	specifications.
Distal Tip	The distal tip shall be smooth, rounded, tapered,	Distal tip is suitable for
Distai Tip	or similarly finished to minimize trauma to	intended clinical use.
	vessels during use.	interface chimear asc.
Radio	The tip of the catheter should be visible under	Device radiopacity is suitable
Detectability	fluoroscopy.	for intended clinical use.
Corrosion	Metallic components of the catheter intended for	Corrosion resistance is suitable
Resistance	fluid path contact shall show no signs of	for intended clinical use and
	corrosion.	met requirements of ISO
		10555-1.
Peak Tensile	6F Catheter force at break ≥15N for distal	Peak tensile force is suitable
Force	section and hub/catheter junction.	for intended clinical use and
	5F Catheter force at break ≥10N for distal	met requirements of ISO
	section and hub/catheter junction.	10555-1.
Fluid leakage	No liquid leakage from hub and catheter shaft at	Device integrity is suitable for
at $>$ 46 psi	46 psi for 30 seconds.	intended clinical use and met
A' T 1	NT 1 1 (1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	requirements of ISO 10555-1.
Air Leakage	No air leakage at hub into syringe when negative	Device integrity is suitable for
	pressure was applied for 15 seconds.	intended clinical use and met
		requirements of ISO 10555-1.
Guaging	The plane of the maximum diameter at the	The device hub met the
	opening of the female conical fitting shall lie	requirements of ISO 80369-7.
C	between the two limit planes of the gauge.	T1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1
Separation	The mating parts separation force is greater than	The device hub met the
Force Unscrewing	35 N.  Test article luer remains attached after applying	requirements of ISO 80369-7.  The device hub met the
Torque	Test article luer remains attached after applying an unscrewing torque not less than 0.02 N m for	requirements of ISO 80369-7.
101940	a minimum of 10 seconds.	requirements of 150 00507-7.
Stress	No stress cracks on the test article hub.	The device hub met the
Cracking		requirements of ISO 80369-7.
Ease of	Components fit together securely with no	The device hub met the
Assembly	resistance observed between the test article luer	requirements of ISO 80369-7.
	and reference fitting.	
Resistance to	Test article luer does not override reference	The device hub met the
Overriding	fitting threads.	requirements of ISO 80369-7.
Particulate	The amount of particulate matter that comes off	The amount and size of
	the device during simulated use testing shall be	particles from the subject
	determined and compared to the predicate	device was comparable to the
a	device.	predicate device.
Static Burst	The catheter was tested to evaluate the burst	Device integrity is suitable for
Pressure	pressure under static conditions per ISO 10555-	intended clinical use and met
Conting	1:2013(E) Annex F.  The outhers was tested 20 times on the friction	requirements of ISO 10555-1.
Coating	The catheter was tested 20 times on the friction	Device tracks easily with no

Lubricity and Durability	tester. The frictional force shall be equivalent to the predicate device and be less than 0.3N.	coating cracking or separation, and is equivalent to the
Duraomity	the predicate device and be less than 0.51v.	predicate device.
Equipment Interface	The catheter shall be compatible with 0.035" guidewire, ≥ 0.088" ID guide catheter/	The device is compatible with the accessories as specified.
	introducer sheath, $\leq 0.027$ " OD microcatheters, and common hemostatic valve.	
Tip	The distal tip should be steam shapeable and	Shapeability of the distal tip
Shapeability	equivalent to the predicate devices.	after steam shaping is equivalent to predicate device.
Kink	No kinks when wrapped around pin gauges of	The device is resistant to
Resistance	clinical use relevant radii.  No kinks noted during simulated use testing.  Shall be equivalent to the predicate devices.	kinking around relevant radii turns.
Simulated Use	The catheter should reach various target locations in the tortuous vessel model; the catheter could be delivered and retracted smoothly with a 0.035" guidewire in the model; no device damage or defects after simulated use.	Device performs as intended under simulated use conditions.
Torque Response	The torque response of the catheter should be no worse than the predicate device.	Device torque response is equivalent to the predicate device.
Torque Strength	No catheter breakage after 50 rotations.	Device torque strength is equivalent to the predicate device.
Pushability/	The pushability/retractability of the catheter in	Device pushability/
Retractability	the tortuous vessel model shall be not worse than the predicate device.	retractability is equivalent to the predicate device.
Catheter	The catheter stiffness shall be equivalent to the	The catheter stiffness is
Stiffness	predicate devices.	equivalent to the predicate device.
Catheter	No flexural fatigue following repeated bending	The catheter flexural fatigue is
Flexural Fatigue	during simulated use testing and repeated hoop stress following pressure and air aspiration testing.	equivalent to the predicate device.
Dynamic	The catheter shall not burst under dynamic	The device met the test
Burst	pressure of 300 psi for 30 seconds.	acceptance criteria.
Flow Rate	The catheter should withstand manual injection of contrast media and saline at the clinically relevant flow rates.	The device can withstand flow rates suitable for intended clinical use.
Ethylene	The residual amount of ethylene oxide in a	Ethylene Oxide Residue met
Oxide Residue	single package should not exceed 10μg/g.	the acceptance criteria per ISO 10993-7:2008.
Sterility	The product shall be sterile.	Sterility of the catheter met the acceptance criteria per ISO 11135:2014.
Bacterial Endotoxins	Endotoxin content shall not be greater than 2.15 EU/ kit.	Bacterial endotoxins met the acceptance criteria per USP <85>.

# • Biocompatibility

The biocompatibility evaluation for the Distal Access Catheter was conducted in accordance with FDA's biocompatibility guidance, "Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process"."

The biological tests were conducted in compliance with the Good Laboratory Practice (GLP) Regulation 21 CFR 58. The results of testing are listed in the table below:

Biocompatibility Test	Result	Conclusion
Cytotoxicity Test (ISO 10993-5) MTT Method, MEM with 10% FBS extract	The cell viability of 100% test article extract was 95.5%.	Non-cytotoxic
Skin Sensitization Test (ISO 10993-10) Guinea Pig Maximization Test, 0.9% Sodium Chloride Injection Extract and Sesame Oil Extract	The positive rate of the test article was 0%.	No significant evidence of skin sensitization
Intracutaneous Reactivity Test (ISO 10993- 10) 0.9% Sodium Chloride Injection Extract and Sesame Oil Extract	The final test article score was calculated to be 0.	Non-irritant
Acute Systemic Toxicity Test (ISO 10993-11) Intravenous 0.9% Sodium Chloride Injection Extract and Sesame Oil Extract	Body weight data were acceptable and equivalent between the corresponding test and control treatment groups.	No significant evidence of systemic toxicity
Acute Systemic Toxicity Test (ISO 10993-11) Intraperitoneal Sesame Oil Extract	Body weight data were acceptable and equivalent between the corresponding test and control treatment groups.	No significant evidence of systemic toxicity
Hemolytic Properties Test (ASTM F756) Direct and Extract Contact Method Rabbit Blood	The hemolysis index was 0.44% (direct contact) and 0.00 (indirect contact).	No influence on hemolytic properties
Partial Thromboplastin Time (PTT) Test (ISO 10993-4) In vitro Human Blood	No significant differences between the sample group and the negative group.	No effect on PTT
In Vivo Thrombogenicity Test (ISO 10993-4) Non-anticoagulated venous implant (NAVI) Model	No significant differences between the test and control articles.	Equivalent to the control article
Pyrogen Test (ISO 10993-11) 0.9% Sodium Chloride Injection Extract Rabbit	No rabbit shows an individual rise in temperature of 0.5 °C or more.	Non-pyrogenic
Complement Activity (C3a, SC5b-9) Test (ISO 10993-4) In vitro Test	No significant difference between the sample group and negative control group.	Equivalent to the negative control group

# VIII. CONCLUSIONS

The data presented in this submission demonstrate the technological similarity and substantial equivalence of the Distal Access Catheter when compared with the predicate devices SOFIA PLUS/Distal Access Catheter(K150366) and SOFIA Distal Access Catheter (K131482, K142014).

The subject and predicate devices,

- have the same indications for use,
- use the same operating principle,
- incorporate the same basic design,
- are packaged and sterilized using similar materials and processes.

In summary, the Distal Access Catheter described in this submission is substantially equivalent to the predicate devices.